Compile Data Set for Download or QSAR
maximum 50k data
Found 500 of ic50 for UniProtKB: P23467
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359101(US10220048, Compound AA11 | US10952992, No. AA11 |...)
Affinity DataIC50:  0.0100nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359101(US10220048, Compound AA11 | US10952992, No. AA11 |...)
Affinity DataIC50:  0.0100nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359101(US10220048, Compound AA11 | US10952992, No. AA11 |...)
Affinity DataIC50:  0.0100nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359101(US10220048, Compound AA11 | US10952992, No. AA11 |...)
Affinity DataIC50:  0.0100nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359121(US10220048, Compound AA31 | US10952992, No. AA31 |...)
Affinity DataIC50:  0.0800nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359106(US10220048, Compound AA16 | US10952992, No. AA16 |...)
Affinity DataIC50:  0.0800nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359121(US10220048, Compound AA31 | US10952992, No. AA31 |...)
Affinity DataIC50:  0.0800nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359106(US10220048, Compound AA16 | US10952992, No. AA16 |...)
Affinity DataIC50:  0.0800nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359121(US10220048, Compound AA31 | US10952992, No. AA31 |...)
Affinity DataIC50:  0.0800nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359106(US10220048, Compound AA16 | US10952992, No. AA16 |...)
Affinity DataIC50:  0.0800nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359121(US10220048, Compound AA31 | US10952992, No. AA31 |...)
Affinity DataIC50:  0.0800nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359106(US10220048, Compound AA16 | US10952992, No. AA16 |...)
Affinity DataIC50:  0.0800nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359113(US10220048, Compound AA23 | US10952992, No. AA23 |...)
Affinity DataIC50:  0.0900nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359113(US10220048, Compound AA23 | US10952992, No. AA23 |...)
Affinity DataIC50:  0.0900nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359113(US10220048, Compound AA23 | US10952992, No. AA23 |...)
Affinity DataIC50:  0.0900nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359113(US10220048, Compound AA23 | US10952992, No. AA23 |...)
Affinity DataIC50:  0.0900nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359099(US10220048, Compound AA9 | US10952992, No. AA9 | U...)
Affinity DataIC50:  0.100nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359118(US10220048, Compound AA28 | US10952992, No. AA28 |...)
Affinity DataIC50:  0.100nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359104(US10220048, Compound AA14 | US10952992, No. AA14 |...)
Affinity DataIC50:  0.100nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359118(US10220048, Compound AA28 | US10952992, No. AA28 |...)
Affinity DataIC50:  0.100nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359104(US10220048, Compound AA14 | US10952992, No. AA14 |...)
Affinity DataIC50:  0.100nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359104(US10220048, Compound AA14 | US10952992, No. AA14 |...)
Affinity DataIC50:  0.100nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359099(US10220048, Compound AA9 | US10952992, No. AA9 | U...)
Affinity DataIC50:  0.100nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359118(US10220048, Compound AA28 | US10952992, No. AA28 |...)
Affinity DataIC50:  0.100nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359099(US10220048, Compound AA9 | US10952992, No. AA9 | U...)
Affinity DataIC50:  0.100nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359118(US10220048, Compound AA28 | US10952992, No. AA28 |...)
Affinity DataIC50:  0.100nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359104(US10220048, Compound AA14 | US10952992, No. AA14 |...)
Affinity DataIC50:  0.100nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359099(US10220048, Compound AA9 | US10952992, No. AA9 | U...)
Affinity DataIC50:  0.100nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359117(US10220048, Compound AA27 | US10952992, No. AA27 |...)
Affinity DataIC50:  0.140nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359117(US10220048, Compound AA27 | US10952992, No. AA27 |...)
Affinity DataIC50:  0.140nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359117(US10220048, Compound AA27 | US10952992, No. AA27 |...)
Affinity DataIC50:  0.140nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359117(US10220048, Compound AA27 | US10952992, No. AA27 |...)
Affinity DataIC50:  0.140nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359091(US10220048, Compound AA1 | US10220048, Compound AA...)
Affinity DataIC50:  0.157nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359091(US10220048, Compound AA1 | US10220048, Compound AA...)
Affinity DataIC50:  0.157nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359091(US10220048, Compound AA1 | US10220048, Compound AA...)
Affinity DataIC50:  0.157nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359091(US10220048, Compound AA1 | US10220048, Compound AA...)
Affinity DataIC50:  0.157nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359096(US10220048, Compound AA6 | US10952992, No. AA6 | U...)
Affinity DataIC50:  0.162nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359096(US10220048, Compound AA6 | US10952992, No. AA6 | U...)
Affinity DataIC50:  0.162nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359096(US10220048, Compound AA6 | US10952992, No. AA6 | U...)
Affinity DataIC50:  0.162nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359096(US10220048, Compound AA6 | US10952992, No. AA6 | U...)
Affinity DataIC50:  0.162nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359120(US10220048, Compound AA30 | US10952992, No. AA30 |...)
Affinity DataIC50:  0.200nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359108(US10220048, Compound AA18 | US10952992, No. AA18 |...)
Affinity DataIC50:  0.200nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359187(US10220048, Compound AA97 | US10952992, No. AA97 |...)
Affinity DataIC50:  0.200nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359178(US10220048, Compound AA88 | US10952992, No. AA88 |...)
Affinity DataIC50:  0.200nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359187(US10220048, Compound AA97 | US10952992, No. AA97 |...)
Affinity DataIC50:  0.200nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359100(US10220048, Compound AA10 | US10952992, No. AA10 |...)
Affinity DataIC50:  0.200nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359108(US10220048, Compound AA18 | US10952992, No. AA18 |...)
Affinity DataIC50:  0.200nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359120(US10220048, Compound AA30 | US10952992, No. AA30 |...)
Affinity DataIC50:  0.200nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359100(US10220048, Compound AA10 | US10952992, No. AA10 |...)
Affinity DataIC50:  0.200nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals

US Patent
LigandPNGBDBM359108(US10220048, Compound AA18 | US10952992, No. AA18 |...)
Affinity DataIC50:  0.200nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 500 total ) | Next | Last >>
Jump to: